JP Morgan Chase
VIGL

JP Morgan Chase’s Vigil Neuroscience VIGL Stock Holding History

JP Morgan Chase’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-396,926
Closed -$3.16M – 7743
2025
Q2 		$3.16M Buy
396,926
+396,544
+103,807% +$1.78M ﹤0.01% 3554
2025
Q1 		$680 Hold
382
– – ﹤0.01% 6670
2024
Q4 		$649 Sell
382
-32
-8% -$94 ﹤0.01% 6779
2024
Q3 		$1.41K Sell
414
-8,723
-95% -$32.3K ﹤0.01% 6681
2024
Q2 		$36.5K Buy
9,137
+2,021
+28% +$6.92K ﹤0.01% 5974
2024
Q1 		$24.3K Sell
7,116
-3,299
-32% -$10.3K ﹤0.01% 6175
2023
Q4 		$35.2K Hold
10,415
– – ﹤0.01% 6114
2023
Q3 		$56.1K Sell
10,415
-2,390
-19% -$16.5K ﹤0.01% 5758
2023
Q2 		$120K Buy
+12,805
New +$121K ﹤0.01% 5377
2022
Q4 		– Sell
-2
Closed – – 7032
2022
Q3 		$0 Sell
2
-212
-99% -$1.55K ﹤0.01% 6884
2022
Q2 		$1K Sell
214
-2,934
-93% -$11.6K ﹤0.01% 6391
2022
Q1 		$22K Buy
+3,148
New +$41.5K ﹤0.01% 6050

Other funds holding VIGL

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

JP Morgan Chase's VIGL Position: Q3 2025 in Review

JP Morgan Chase sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 396,926 shares — an estimated $3.16M sold.

JP Morgan Chase first reported a position in VIGL in Q1 2022 and held it in 12 quarters. The position peaked at $3.16M in Q2 2025. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.

  • JP Morgan Chase reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 396,926 Vigil Neuroscience shares in Q3 2025, an estimated $3.16M.
  • JP Morgan Chase first reported a position in Vigil Neuroscience in Q1 2022 and held it in 12 quarters.
  • JP Morgan Chase's Vigil Neuroscience position peaked at $3.16M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.